

ASX ANNOUNCEMENT

16 June 2016

GlaxoSmithKline Extends Service Agreement with MedAdvisor

Highlights

- GlaxoSmithKline (GSK) Australia extends its services agreement with MedAdvisor for a further 12 months
- GSK will continue utilising MedAdvisor's medication management platform to provide relevant information for patients prescribed three medicines within GSK Australia's respiratory portfolio.
- Agreement will generate Patient Engagement Program (PEP), formerly known as Medication Training and Adherence Campaigns (MTAC), revenue for MedAdvisor.
- Allows GSK Australia to leverage the MedAdvisor platform to support patients on the safe and effective use of these medicines.

MedAdvisor Limited (ASX: **MDR**, the **Company**), Australia's leading digital medication adherence company, is pleased to announce that the Australian arm of leading global pharmaceutical company, GlaxoSmithKline Australia Pty Ltd (GSK) has extended its services agreement with MedAdvisor for a further 12 months.

Under the agreement, GSK Australia will continue providing tailored messages to patients prescribed medicines within GSK Australia's respiratory portfolio. These Patient Engagement Programs will be designed to support and improve the effective and safe use of these medicines.

GSK is a global pharmaceutical company, headquartered in London that produces a number of the world's leading medicines and vaccines. It has been using the MedAdvisor platform since February 2015 and under the extended services agreement, will continue using the platform for a further 12 months.

The Company will receive Patient Engagement Program revenue from GSK for the use of the platform.

Geoff McDonald, VP & General Manager of GlaxoSmithKline Australia, commented

"Manufacturers play a vital role in supporting patients in the effective and safe use of medicines prescribed by their treating medical practitioner. We are pleased to continue working with MedAdvisor, to better engage and support patients taking medicines within our respiratory portfolio."

Robert Read, CEO of MedAdvisor commented:

"GlaxoSmithKline Australia's continued engagement with MedAdvisor validates the value we continue to provide to both patients and pharmaceutical manufacturers. We look forward to working closely with GSK Australia in supporting their patients prescribed with GSK medicines."

-ENDS-

For more information

Robert Read, CEO
MedAdvisor
Tel: +61 3 9095 3036
robertr@medadvisor.com.au

Matthew Wu
Media and Capital Partners
Tel: +61 433 634 706
matthew.wu@mcpartners.com.au

About MedAdvisor

MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. Founded with a desire to simplify medication management, the highly automated and intuitive Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records. Available free on mobile and internet devices, the platform also incorporates a variety of valuable and convenient features including reminders and pre-ordering of medications, which together improves adherence by approximately 20%.

Since launching in 2013, MedAdvisor has over 140,000 registered users and is connected with a third of pharmacies across Australia. With the recent GP software integration enabling patients to order script renewals remotely from their doctor; MedAdvisor continues to lead the way in delivering innovative patient centred health solutions.

About GlaxoSmithKline

GlaxoSmithKline (LSE:GSK), (NYSE:GSK) is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Headquartered in London, GSK is involved in the creation, discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK's principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV).